Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities

SARS-CoV-2 has caused a global health disaster with millions of death worldwide, and the substantial proportion of asymptomatic carriers poses a huge threat to public health. The long-term antibody responses and neutralization activity during natural asymptomatic SARS-CoV-2 infection are unknown. In...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaodong Tian, Wenguo Jiang, He Zhang, XiXi Lu, Libo Li, Wenjun Liu, Jing Li
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	COVID-19 SARS-CoV-2 antibody response asymptomatic infection persistence Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/2039b69561a94ffba6a6540040479082
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2039b69561a94ffba6a6540040479082
record_format	dspace
spelling	oai:doaj.org-article:2039b69561a94ffba6a65400404790822021-11-10T08:15:21ZPersistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities1664-302X10.3389/fmicb.2021.789374https://doaj.org/article/2039b69561a94ffba6a65400404790822021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmicb.2021.789374/fullhttps://doaj.org/toc/1664-302XSARS-CoV-2 has caused a global health disaster with millions of death worldwide, and the substantial proportion of asymptomatic carriers poses a huge threat to public health. The long-term antibody responses and neutralization activity during natural asymptomatic SARS-CoV-2 infection are unknown. In this study, we used enzyme-linked immunosorbent assays (ELISA) and neutralization assay with purified SARS-CoV-2S and N proteins to study the antibody responses of 156 individuals with natural asymptomatic infection. We found robust antibody responses to SARS-CoV-2 in 156 patients from 6 to 12 months. Although the antibody responses gradually decreased, S-IgG was more stable than N-IgG. S-IgG was still detected in 79% of naturally infected individuals after 12 months of infection. Moderate to potent neutralization activities were also observed in 98.74% of patients 6 months after infection. However, this proportion decreased at 8-month (46.15%) and 10-month (39.11%) after infection, respectively. Only 23.72% of patients displayed potent neutralization activity at 12 months. This study strongly supports the long-term presence of antibodies against SARS-CoV-2 in individuals with natural asymptomatic infection, although the magnitude of the antibody responses started to cripple 6 months after infection.Xiaodong TianXiaodong TianWenguo JiangHe ZhangXiXi LuLibo LiWenjun LiuWenjun LiuWenjun LiuWenjun LiuJing LiJing LiFrontiers Media S.A.articleCOVID-19SARS-CoV-2antibody responseasymptomatic infectionpersistenceMicrobiologyQR1-502ENFrontiers in Microbiology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 SARS-CoV-2 antibody response asymptomatic infection persistence Microbiology QR1-502
spellingShingle	COVID-19 SARS-CoV-2 antibody response asymptomatic infection persistence Microbiology QR1-502 Xiaodong Tian Xiaodong Tian Wenguo Jiang He Zhang XiXi Lu Libo Li Wenjun Liu Wenjun Liu Wenjun Liu Wenjun Liu Jing Li Jing Li Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
description	SARS-CoV-2 has caused a global health disaster with millions of death worldwide, and the substantial proportion of asymptomatic carriers poses a huge threat to public health. The long-term antibody responses and neutralization activity during natural asymptomatic SARS-CoV-2 infection are unknown. In this study, we used enzyme-linked immunosorbent assays (ELISA) and neutralization assay with purified SARS-CoV-2S and N proteins to study the antibody responses of 156 individuals with natural asymptomatic infection. We found robust antibody responses to SARS-CoV-2 in 156 patients from 6 to 12 months. Although the antibody responses gradually decreased, S-IgG was more stable than N-IgG. S-IgG was still detected in 79% of naturally infected individuals after 12 months of infection. Moderate to potent neutralization activities were also observed in 98.74% of patients 6 months after infection. However, this proportion decreased at 8-month (46.15%) and 10-month (39.11%) after infection, respectively. Only 23.72% of patients displayed potent neutralization activity at 12 months. This study strongly supports the long-term presence of antibodies against SARS-CoV-2 in individuals with natural asymptomatic infection, although the magnitude of the antibody responses started to cripple 6 months after infection.
format	article
author	Xiaodong Tian Xiaodong Tian Wenguo Jiang He Zhang XiXi Lu Libo Li Wenjun Liu Wenjun Liu Wenjun Liu Wenjun Liu Jing Li Jing Li
author_facet	Xiaodong Tian Xiaodong Tian Wenguo Jiang He Zhang XiXi Lu Libo Li Wenjun Liu Wenjun Liu Wenjun Liu Wenjun Liu Jing Li Jing Li
author_sort	Xiaodong Tian
title	Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
title_short	Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
title_full	Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
title_fullStr	Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
title_full_unstemmed	Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
title_sort	persistence of the sars-cov-2 antibody response in asymptomatic patients in correctional facilities
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/2039b69561a94ffba6a6540040479082
work_keys_str_mv	AT xiaodongtian persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT xiaodongtian persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT wenguojiang persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT hezhang persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT xixilu persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT liboli persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT wenjunliu persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT wenjunliu persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT wenjunliu persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT wenjunliu persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT jingli persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT jingli persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities
_version_	1718440355601317888

Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities

Ejemplares similares